[Standards, Options and Recommendations for the use of PET-FDG in cancerology. Results in urological cancers].
Centre Eugène-Marquis, Rennes
Patrick
P
Bourguet
D001859:Bone Neoplasms / Q000000981:diagnostic imaging / Q000556:secondary; D019788:Fluorodeoxyglucose F18; D006801:Humans; D007680:Kidney Neoplasms / Q000000981:diagnostic imaging; D008297:Male; D009364:Neoplasm Recurrence, Local / Q000000981:diagnostic imaging; D011471:Prostatic Neoplasms / Q000000981:diagnostic imaging*; D019275:Radiopharmaceuticals; D018239:Seminoma / Q000000981:diagnostic imaging; D013736:Testicular Neoplasms / Q000000981:diagnostic imaging*; D014055:Tomography, Emission-Computed / Q000592:standards*; D001749:Urinary Bladder Neoplasms / Q000000981:diagnostic imaging; D014571:Urologic Neoplasms / Q000000981:diagnostic imaging* / Q000188:drug therapy
D019275:Radiopharmaceuticals; D019788:Fluorodeoxyglucose F18